A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

NCT02212067 ↗

Phase 1 Completed 87 enrolled Novo Nordisk A/S

RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of the trial is to investigate the effects of semaglutide on ß-cell function in subjects with type 2 diabetes.

Timeline

Start: 2014-08-11
Primary completion: 2015-05-11
Completion: 2015-05-11

Outcome

Met primary endpoint

paper Following IVGTT, for insulin, both AUC0-10min and AUC10-120min were significantly increased with semaglutide PMID 28526920 ↗

paper (estimated treatment ratio [95% CI] 3.02 [2.53, 3.60] and 2.10 [1.86, 2.37], respectively; p < 0.0001). PMID 28526920 ↗

Publications

Results Kapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017 Aug;60(8):1390-1399. doi: 10.1007/s00125-017-4289-0. Epub 2017 May 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Semaglutide	Peptide	1 mg	Subcutaneous